SCHEMBL7965219

SCHEMBL7965219

COC(=O)c1ccc(NC(=N)N)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.52
F10 P00742 1/20 0.52
PLG P00747 1/20 0.52
PLAU P00749 1/20 0.52
PLAT P00750 1/20 0.52
KLK1 P06870 2/20 0.50
KLK5 Q9Y337 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
HDAC1 Q13547 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
CDK1 P06493 1/20 0.41
GAA P10253 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15598651 0.83 SMN1; SMN2 (0.69) SMN1; SMN2HDAC1TDP1MEN1KMT2A
SCHEMBL7978757 0.83 KLK1 (0.48) F2F10PLGPLAUPLAT
SCHEMBL29116429 0.83 SMN1; SMN2 (0.51) F2F10PLGPLAUPLAT
SCHEMBL12198690 0.82 TDP1 (0.52) KLK1KLK5SMN1; SMN2TDP1MAPT
SCHEMBL28776120 0.81 SMN1; SMN2 (0.45) F2F10PLGPLAUPLAT
Hydrochloric Acid SCHEMBL16701818 0.81 TDP1 (0.51) KLK1KLK5SMN1; SMN2TDP1MAPT
SCHEMBL4833247 0.79 SMN1; SMN2 (0.46) SMN1; SMN2TDP1MAPTMEN1KMT2A
SCHEMBL28439983 0.79 CYP1A2 (0.57) SMN1; SMN2TDP1MAPTMEN1KMT2A
SCHEMBL18115703 0.78 KLK1 (0.44) F2F10PLGPLAUPLAT
SCHEMBL17244480 0.78 HDAC1 (0.58) F2F10PLGPLAUPLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US disclosed
WO-2010009155-A2 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD COLORADO, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 F2 4396/4885F10 3611/4885PLG 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.